Subtype
Urinary Tract Neoplasm
CI-CAN-00001627Explore in graph →
Non-malignant558 active trials14 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001627Explore in graph →
Clinical trials
2,186 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05867303 | A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | unknown | Phase 1 | 48 | RemeGen Co., Ltd.INDUSTRY | 2 | Aug 16, 2024 | clinicaltrials |
| NCT06551233 |
| Safety and Efficacy of 9MW2821 in the Treatment of High-risk Non-muscle-invasive Bladder Cancer (NMIBC) |
| unknown |
| Phase 1 |
| 30 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER |
| 1 |
| Aug 13, 2024 |
| clinicaltrials |
| NCT06427291 | Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients | unknown | Phase 1 | 20 | Fudan UniversityOTHER | 1 | May 23, 2024 | clinicaltrials |
| NCT04134000 | Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)(BladderGATE) | unknown | Phase 1 | 40 | Fundacion OncosurNETWORK | 1 | May 21, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT03549715 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma(NEMIO) | unknown | Phase 1 / Phase 2 | 121 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05829057 | The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1 | unknown | Phase 1 | 10 | Zhejiang UniversityOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06221774 | Safety and Efficacy of TT-00420 Tablets Combined With Toripalimab Injection in Advanced Urological Tumors | unknown | Phase 1 / Phase 2 | 42 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT05259319 | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)(IMMUNOs-SBRT) | unknown | Phase 1 | 92 | Centre Georges Francois LeclercOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06034015 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers | unknown | Phase 1 | 48 | Jiangsu Yahong Meditech Co., Ltd aka AsierisINDUSTRY | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT03475953 | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors(REGOMUNE) | unknown | Phase 1 / Phase 2 | 747 | Institut BergoniéOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT04799847 | Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine | unknown | Phase 1 / Phase 2 | 161 | LintonPharm Co.,Ltd.INDUSTRY | 1 | Feb 13, 2023 | clinicaltrials |
| NCT03844256 | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study(CRIMI) | unknown | Phase 1 / Phase 2 | 50 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT04819399 | Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | unknown | Phase 1 | 30 | Lindis Biotech GmbHINDUSTRY | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05235607 | Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors | unknown | Phase 1 | 60 | Sichuan UniversityOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT04603846 | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT05108077 | Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells | unknown | Phase 1 / Phase 2 | 20 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusOTHER_GOV | 1 | Jan 14, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05124106 | In Vivo Proof-of-principle Study of Raman Spectroscopy in Trial Participants With Bladder Tumours | unknown | Phase 1 | 30 | University Hospital Bispebjerg and FrederiksbergOTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05086666 | A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547 | unknown | Phase 1 / Phase 2 | 108 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Oct 21, 2021 | clinicaltrials |
| NCT04871334 | Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma | unknown | Phase 1 | 76 | Shandong TheraWisdom Biopharma Co., Ltd.INDUSTRY | 1 | Jul 23, 2021 | clinicaltrials |
| NCT04922047 | Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)(TACBIN-01) | unknown | Phase 1 / Phase 2 | 6 | RenJi HospitalOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT04264936 | A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer | unknown | Phase 1 / Phase 2 | 36 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03676946 | A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Locally Advanced and Metastatic Urothelial Carcinoma | unknown | Phase 1 / Phase 2 | 15 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Sep 26, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT01124682 | 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder | unknown | Phase 1 | 60 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 26, 2013 | clinicaltrials |
| NCT00959868 | A Study for Treatment of Superficial Bladder Cancer Using OGX-427 | unknown | Phase 1 | 36 | Vancouver Coastal HealthOTHER_GOV | 1 | Feb 13, 2012 | clinicaltrials |
| NCT00818350 | Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer | unknown | Phase 1 / Phase 2 | 25 | Campania Younger Oncologists AssociationOTHER | 0 | Jan 7, 2009 | clinicaltrials |
| NCT00109655 | Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure | unknown | Phase 1 | 75 | Cell GenesysINDUSTRY | 2 | Oct 3, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Dec 18, 2024source: clinicaltrials